Why Is Genius Sports (GENI) Stock Up +9.83% Today?
Key Takeaways
- GENI shares climbed roughly 9.83% in today's session, building on a multi-session rebound from recent lows.
- The primary catalyst was JPMorgan's initiation of coverage with an Overweight rating and an $8 price target.
- The analyst cited "diversified above-market growth," improving profitability, attractive valuation, and untapped prediction-market optionality.
- The move comes after a steep year-to-date decline of roughly 47%, leaving the stock trading at a depressed multiple versus peers.
- Traders are watching whether the stock can sustain momentum above key technical levels and hold its post-initiation gains.
Opening Summary
GENI, or Genius Sports Limited, is a sports data and technology company that supplies real-time statistics, official data feeds, and betting infrastructure to leagues, sportsbook operators, advertisers, and media partners worldwide. The stock rallied sharply today, gaining about 9.83% to trade near $6.37, up from a prior session close of $5.80. The advance was driven squarely by a bullish initiation of coverage from JPMorgan, which began following the company with an Overweight rating and a price target well above current levels.
JPMorgan Initiates Coverage With an Overweight Rating
The dominant catalyst behind today's price rally was a fresh analyst endorsement. JPMorgan initiated coverage of GENI with an Overweight rating and an $8 price target, representing roughly 38% upside from Thursday's close. Analyst Samuel Nielsen framed the call around what he described as a "scarce combo of diversified above-market growth, strong execution, improving profitability and free cash flow, and attractive valuation," adding that the stock carries optionality from the emerging prediction-markets segment that is not yet reflected in Street estimates.
The endorsement carries weight because GENI has been heavily de-rated this year. The shares entered the session down roughly 47% year to date, pressured by investor concerns that traditional sportsbooks face intensifying competition from prediction markets and by lingering skepticism over the company's acquisition of digital sports and gaming media network Legend. JPMorgan's view is that this punishment has left the stock trading at an unjustified discount — about five times estimated fiscal 2027 enterprise value — and "meaningfully below" larger industry players such as DKNG and FLUT.
Consensus Aligns With the Bullish Call
The JPMorgan initiation did not arrive in a vacuum. Of the 22 analysts covering the company, 19 already maintain a buy or strong-buy rating, underscoring that Wall Street's broader view remains constructive even as the stock's price has lagged. The fresh Overweight rating and an explicit price target helped crystallize that optimism, giving traders a concrete trigger to act on after months of selling pressure. The result was an earnings-style reaction driven not by financial results but by a re-rating argument centered on valuation and execution.
Market Context and Trading Activity
The move reflected genuine buying interest rather than a drift higher on light volume. Trading activity was markedly elevated relative to the stock's typical daily turnover, consistent with institutional and retail investors responding to the initiation note. The stock's rebound also fits within a broader narrative of investors rotating toward beaten-down names with improving fundamentals, though the rally in GENI was notably more pronounced than the action in the broader market, confirming the company-specific nature of the catalyst.
From a technical standpoint, the advance pushed the stock decisively above the prior session's close and lifted it off the lower end of its recent trading range, helping recapture a portion of the losses sustained during the sharp sell-off seen earlier in September.
What Comes Next for GENI
Looking ahead, investors will focus on whether GENI can convert its top-line momentum into sustained profitability and free cash flow — the central thesis of the JPMorgan call. The company recently raised its full-year 2026 revenue guidance to a range of $1.005 billion to $1.025 billion, yet it remains loss-making, so margin execution will be closely scrutinized in upcoming reports. The performance of its prediction-market initiatives and the integration of Legend will also shape sentiment.
Key risks remain. Competition from prediction markets continues to weigh on the sports-betting ecosystem, rising data-rights and technology costs could pressure margins, and the stock's elevated volatility means gains can reverse quickly. Traders will be watching upcoming earnings, sector data, and any further analyst actions for confirmation that the re-rating has staying power.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots currently performing best under prevailing market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Explore the Trending AI Robots section to see which strategies are gaining momentum right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GENI's RSI Oscillator ascending out of oversold territory
The RSI Indicator for GENI moved out of oversold territory on September 22, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 23 of the 25 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 58 cases where GENI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The 50-day moving average for GENI moved above the 200-day moving average on September 02, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +6.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where GENI advanced for three days, in 205 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
GENI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GENI as a result. In 79 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
GENI moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GENI crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GENI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for GENI entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. GENI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.270) is normal, around the industry mean (1.312). P/E Ratio (59.172) is within average values for comparable stocks, (399.801). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (16.804). Dividend Yield (0.000) settles around the average of (0.014) among similar stocks. P/S Ratio (2.232) is also within normal values, averaging (69.903).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GENI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry InternetSoftwareServices
Advertisement